Dupuytren’s disease mainly occurs due to the formation of fibrous cords in the palm, which causes the fingers to bend inward towards the palm. This disease can lead to loss of hand function if left untreated. The symptoms are usually seen among people aged 50 years and above. The exact cause of Dupuytren’s disease is unknown but may be genetic or due to repeated injury to palms or conditions like diabetes, HIV/AIDS etc. Early diagnosis and timely treatment helps prevent loss of joint movement. Recent technological advancements in diagnostic imaging, minimally invasive procedures and pharmaceutical treatments have enhanced the management of Dupuytren’s disease.
The Global Dupuytren’s Disease Market is estimated to be valued at Us$ 4.3 Bn in 2024 and is expected to exhibit a CAGR Of 4.6% over the forecast period 2024 To 2030.
Key players operating in the Global Dupuytrens Disease Market Demand are Endo International Plc, Bristol-Meyers Squibb Company, Spear Pharmaceuticals, GSK Plc., AstraZeneca, Hikma Pharmaceuticals Plc, LEO Pharma A/S, Fresenius Kabi AG, Bayer AG, Novartis AG, Pfizer Inc., Nantong Jinghua Pharmaceutical Co., Ltd., and Actiza Pharmaceutical Pvt. Ltd., 180 Life Sciences Corp.
The growing prevalence of diabetes and rising geriatric population prone to Dupuytren’s disease present significant growth opportunities. Technological developments in minimally invasive procedures such as needle aponeurotomy and collagenase clostridium histolyticum injection have enabled improved treatment outcomes.
Increasing public awareness about Dupuytren’s disease and availability of effective treatment options coupled with supportive government initiatives are expected to drive the market growth during the forecast period. Additionally, the rising incidence of trigger conditions like diabetes and alcoholism is contributing to the disease burden. Growing healthcare expenditure by governments worldwide on chronic disease management will further aid expansion of this market.
Current Challenges in Global Dupuytrens Disease Market
The global Dupuytrens disease market is facing few significant challenges which are limiting its growth potential. First and foremost, there is lack of approved drug therapies for treatment of Dupuytrens disease. Currently, surgery and injections are the only treatment options available which have their own set of limitations and risks. Secondly, the exact pathogenesis and cause of Dupuytrens disease is still unknown which is hindering development of targeted and novel drug therapies. Finding potential drug targets for developing effective pharmacological interventions continues to be a major hurdle. Additionally, low disease awareness among general public and difficulty in early diagnosis are other important challenges impeding market growth.
Strength: Non-surgical treatments such as collagenase clostridium histolyticum injection provide minimally invasive options. Growing research activities focusing on understanding disease pathophysiology.
Weakness: Lack of approved drug therapies limiting treatment landscape. Exact cause and pathogenesis still unknown posing challenges in new target identification.
Opportunity: Large patient pool suffering from condition represents significant commercial opportunity. Rising health expenditure in emerging nations to boost market prospects.
Threats: Presence of alternative nonsurgical treatments including physical therapy can impede drug uptake. Stringent regulatory processes for approval of new formulations.
North America currently dominates the global Dupuytrens disease market in terms of value primarily due to large patient population, rising awareness levels and availability of advanced treatment facilities in the region. The U.S. alone accounts for over 40% of total market revenue owing to its highly developed healthcare infrastructure and high adoption of minimally invasive procedures.
Asia Pacific region is identified as the fastest growing regional market for Dupuytrens disease attributed to growing geriatric population susceptible to condition prevalence, increasing healthcare expenditures, rising medical tourism and rapidly developing pharmaceutical industry in the region. Countries like India, China and Japan are expected to showcase high demand over the forecast period supported by expanding medical facilities, large untapped patient base and favorable government policies.
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it